Peng Xie
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Peng Xie has a total of 22 co-authors. Here are the top co-authors by number of shared publications:
Yanmei Miao
Department of Critical Care Medicine, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China
5 shared publicationsLeiyu Xie
Department of Critical Care Medicine, The Second Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, China
4 shared publicationsShaolin Chen
Department of Nursing of Affiliated Hospital, Zunyi Medical University, Zunyi, China
4 shared publicationsJun Yang
3 shared publicationsMin Li
3 shared publicationsXinglong Ma
Department of Critical Care Medicine, The Third Affiliated Hospital (The First People’s Hospital of Zunyi), Zunyi Medical University, Zunyi, China
3 shared publications
Latest Publications
- Open Access
- 17 November 2026
- Published by Springer Nature in Cell Biology and Toxicology
Redox-Regulated Cell-Death Crosstalk at the Alveolar–Capillary Barrier in Sepsis-Associated Lung Injury
- 17 November 2026
- Published by Springer Nature in Cell Biology and Toxicology
Open AccessRedox-Regulated Cell-Death Crosstalk at the Alveolar–Capillary Barrier in Sepsis-Associated Lung Injury
- Open Access
- 18 September 2026
- Published by Springer Nature in Nutrition & Metabolism
Ketogenic diet mitigates sepsis-related acquired weakness in conjunction with SIRT3 upregulation and macrophage M2 polarization
- 18 September 2026
- Published by Springer Nature in Nutrition & Metabolism
Open AccessKetogenic diet mitigates sepsis-related acquired weakness in conjunction with SIRT3 upregulation and macrophage M2 polarization
- Open Access
- 16 October 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-20
Leptin’s potential mechanisms in ICU-acquired weakness
Intensive care unit-acquired weakness (ICU-AW) represents a prevalent and debilitating complication among critically ill patients, distinguished by profound skeletal muscle atrophy and functional deterioration. Leptin, a hormone predominantly released by adipose tissue, has gained recognition for its regulatory roles in appetite control, energy homeostasis, and muscle metabolism. Recent evidence indicates that leptin May contribute to ICU-AW pathogenesis through dual protective and detrimental mechanisms. During physiological conditions, leptin supports muscle preservation by enhancing anabolic signaling while suppressing catabolic processes. The hormone modulates essential pathways, including the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, Forkhead Box O (FOXO) transcription factors, and AMP-activated protein kinase (AMPK), which collectively promote protein synthesis and energy utilization in skeletal muscle. Nevertheless, throughout critical illness, leptin signaling becomes frequently compromised. Increased leptin concentrations may inappropriately stimulate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and nuclear factor-κB (NF-κB) signalling pathways, initiating the production of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines promote muscle wasting through insulin-like growth factor-1 (IGF-1) inhibition, enhanced insulin resistance, and compromised protein synthesis. Furthermore, they stimulate SPRY domain-containing SOCS box protein 1 (SPSB1) expression, which disrupts myocyte fusion and myogenic differentiation. Compounding these consequences, mitochondrial dysfunction, prevalent in critically ill patients, impairs AMPK activity, further hindering muscle regeneration and energy metabolism. In the later stages of critical illness, leptin levels typically decrease, leading to reduced IGF-1 production, disrupted FOXO regulation, and persistent suppression of AMPK signaling. These alterations worsen muscle atrophy and impede recovery. In summary, leptin demonstrates a dual function in ICU-AW, exhibiting both protective and pathological influences based on the illness phase and context. A deeper understanding of its intricate regulatory mechanisms could provide valuable insights into ICU-AW pathogenesis and potential therapeutic strategies.
- 16 October 2025
- Published by Springer Nature in Lipids in Health and Disease
- Vol. 24 (1) , 1-20
Open AccessLeptin’s potential mechanisms in ICU-acquired weakness
Intensive care unit-acquired weakness (ICU-AW) represents a prevalent and debilitating complication among critically ill patients, distinguished by profound skeletal muscle atrophy and functional deterioration. Leptin, a hormone predominantly released by adipose tissue, has gained recognition for its regulatory roles in appetite control, energy homeostasis, and muscle metabolism. Recent evidence indicates that leptin May contribute to ICU-AW pathogenesis through dual protective and detrimental mechanisms. During physiological conditions, leptin supports muscle preservation by enhancing anabolic signaling while suppressing catabolic processes. The hormone modulates essential pathways, including the phosphoinositide 3-kinase (PI3K)/protein kinase B (Akt) pathway, Forkhead Box O (FOXO) transcription factors, and AMP-activated protein kinase (AMPK), which collectively promote protein synthesis and energy utilization in skeletal muscle. Nevertheless, throughout critical illness, leptin signaling becomes frequently compromised. Increased leptin concentrations may inappropriately stimulate the Janus kinase/signal transducer and activator of transcription (JAK/STAT) and nuclear factor-κB (NF-κB) signalling pathways, initiating the production of pro-inflammatory cytokines including tumor necrosis factor-α (TNF-α), interleukin-1 (IL-1), and interleukin-6 (IL-6). These cytokines promote muscle wasting through insulin-like growth factor-1 (IGF-1) inhibition, enhanced insulin resistance, and compromised protein synthesis. Furthermore, they stimulate SPRY domain-containing SOCS box protein 1 (SPSB1) expression, which disrupts myocyte fusion and myogenic differentiation. Compounding these consequences, mitochondrial dysfunction, prevalent in critically ill patients, impairs AMPK activity, further hindering muscle regeneration and energy metabolism. In the later stages of critical illness, leptin levels typically decrease, leading to reduced IGF-1 production, disrupted FOXO regulation, and persistent suppression of AMPK signaling. These alterations worsen muscle atrophy and impede recovery. In summary, leptin demonstrates a dual function in ICU-AW, exhibiting both protective and pathological influences based on the illness phase and context. A deeper understanding of its intricate regulatory mechanisms could provide valuable insights into ICU-AW pathogenesis and potential therapeutic strategies.
- Open Access
- 2 July 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 1-13
Biomarkers for intensive care unit-acquired weakness: a systematic review for prediction, diagnosis and prognosis
- 2 July 2025
- Published by Elsevier in Annals of Intensive Care
- Vol. 15 (1) , 1-13
Open AccessBiomarkers for intensive care unit-acquired weakness: a systematic review for prediction, diagnosis and prognosis
- Open Access
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 16, 1520669
Potential relationship between cuproptosis and sepsis-acquired weakness: an intermediate role for mitochondria
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Skeletal muscle atrophy due to critical illness is a common phenomenon in the intensive care unit (ICU) and is referred to as ICU-acquired weakness (ICU-AW). The occurrence of ICU-AW in patients with sepsis is known as sepsis-acquired weakness (SAW). Furthermore, it is well known that maintaining normal muscle function closely relates to mitochondrial homeostasis. Once mitochondrial function is impaired, both muscle quality and function are affected. Copper plays a key role in mitochondrial homeostasis as a transition metal that regulates the function and stability of various enzymes. Copper is also involved in oxidation-reduction reactions, and intracellular copper overload causes oxidative stress and induces cell death. Previous studies have shown that excess intracellular copper induces cell death by targeting lipid-acylated proteins that regulate the mitochondrial tricarboxylic acid (TCA) cycle, which differs from the known canonical mechanisms of regulated cell death. Furthermore, inhibitors of cell death, such as apoptosis, necroptosis, pyroptosis and ferroptosis, are not effective in preventing copper-induced cell death. This new form of cell death has been termed “Cuproptosis”; however, the mechanism by which copper-induced cell death is involved in SAW remains unclear. In this paper, we review the possible relationship between cuproptosis and SAW. Cuproptosis may be involved in regulating the pathological mechanisms of SAW through mitochondria-related signaling pathways, mitochondria-related ferroptosis mechanisms, and mitochondria-related genes, and to provide new ideas for further investigations into the mechanism of SAW.
- 20 March 2025
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 16, 1520669
Open AccessPotential relationship between cuproptosis and sepsis-acquired weakness: an intermediate role for mitochondria
Sepsis is defined as a life-threatening organ dysfunction caused by a dysregulated host response to infection. Skeletal muscle atrophy due to critical illness is a common phenomenon in the intensive care unit (ICU) and is referred to as ICU-acquired weakness (ICU-AW). The occurrence of ICU-AW in patients with sepsis is known as sepsis-acquired weakness (SAW). Furthermore, it is well known that maintaining normal muscle function closely relates to mitochondrial homeostasis. Once mitochondrial function is impaired, both muscle quality and function are affected. Copper plays a key role in mitochondrial homeostasis as a transition metal that regulates the function and stability of various enzymes. Copper is also involved in oxidation-reduction reactions, and intracellular copper overload causes oxidative stress and induces cell death. Previous studies have shown that excess intracellular copper induces cell death by targeting lipid-acylated proteins that regulate the mitochondrial tricarboxylic acid (TCA) cycle, which differs from the known canonical mechanisms of regulated cell death. Furthermore, inhibitors of cell death, such as apoptosis, necroptosis, pyroptosis and ferroptosis, are not effective in preventing copper-induced cell death. This new form of cell death has been termed “Cuproptosis”; however, the mechanism by which copper-induced cell death is involved in SAW remains unclear. In this paper, we review the possible relationship between cuproptosis and SAW. Cuproptosis may be involved in regulating the pathological mechanisms of SAW through mitochondria-related signaling pathways, mitochondria-related ferroptosis mechanisms, and mitochondria-related genes, and to provide new ideas for further investigations into the mechanism of SAW.
- Open Access
- 28 November 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1484856
Ketogenic diet in treating sepsis-related acquired weakness: is it friend or foe?
Background: Sepsis is the body’s extreme response to an infection leading to organ dysfunction. Sepsis-related acquired weakness (SAW), a critical illness closely related to metabolic disorders, is characterized by generalized sepsis-induced skeletal muscle weakness, mainly manifesting as symmetrical atrophy of respiratory and limb muscles. Muscle accounts for 40% of the body’s total mass and is one of the major sites of glucose and energy absorption. Diet affects skeletal muscle metabolism, which further impacts physiology and signaling pathways. The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that has shown benefits in patients with a variety of neuromuscular disorders. Patients with SAW are in a hypermetabolic state and can consume approximately 1% of total body muscle mass in a day. Due to the decreased total body energy expenditure secondary to starvation, skeletal muscles enter a low metabolic state, with reduced gluconeogenesis and protein consumption and elevated levels of ketone bodies. The latest research suggests that KD may be a new strategy for SAW prevention and treatment, but its mechanism is still unclear.Objective: Our article aims to explore the effect and mechanism of KD on SAW. And we hope that our review will inspire further research on the KD and foster the exploration of novel strategies for combating SAW.Methods: Search medical databases and related academic websites, using keywords such as “Sepsis-related acquired weakness,” “ketogenic diet,” and “skeletal muscle,” and select representative literature. Using the method of induction and summary, analyze the effect and mechanism of KD on SAW.Results: Compared with early nutrition, KD has a more protective effect on SAW, but its mechanism is complex. Firstly, KD can alter energy metabolism substrates to affect SAW’s energy metabolism; Secondly, KD can directly act as a signaling molecule to improve mitochondrial function in skeletal muscle and stimulate skeletal muscle regeneration signaling molecules; Thirdly, KD can affect the gut microbiota to exert anti-inflammatory effects, enhance immunity, and thus protect SAW.Conclusion: KD has a protective effect on SAW, which includes improving energy metabolism, stimulating muscle regeneration signals, optimizing gut microbiota composition, and reducing inflammation and oxidative stress.
- 28 November 2024
- Published by Frontiers Media SA in Frontiers in Nutrition
- Vol. 11, 1484856
Open AccessKetogenic diet in treating sepsis-related acquired weakness: is it friend or foe?
Background: Sepsis is the body’s extreme response to an infection leading to organ dysfunction. Sepsis-related acquired weakness (SAW), a critical illness closely related to metabolic disorders, is characterized by generalized sepsis-induced skeletal muscle weakness, mainly manifesting as symmetrical atrophy of respiratory and limb muscles. Muscle accounts for 40% of the body’s total mass and is one of the major sites of glucose and energy absorption. Diet affects skeletal muscle metabolism, which further impacts physiology and signaling pathways. The ketogenic diet (KD) is a high-fat, low-carbohydrate diet that has shown benefits in patients with a variety of neuromuscular disorders. Patients with SAW are in a hypermetabolic state and can consume approximately 1% of total body muscle mass in a day. Due to the decreased total body energy expenditure secondary to starvation, skeletal muscles enter a low metabolic state, with reduced gluconeogenesis and protein consumption and elevated levels of ketone bodies. The latest research suggests that KD may be a new strategy for SAW prevention and treatment, but its mechanism is still unclear.Objective: Our article aims to explore the effect and mechanism of KD on SAW. And we hope that our review will inspire further research on the KD and foster the exploration of novel strategies for combating SAW.Methods: Search medical databases and related academic websites, using keywords such as “Sepsis-related acquired weakness,” “ketogenic diet,” and “skeletal muscle,” and select representative literature. Using the method of induction and summary, analyze the effect and mechanism of KD on SAW.Results: Compared with early nutrition, KD has a more protective effect on SAW, but its mechanism is complex. Firstly, KD can alter energy metabolism substrates to affect SAW’s energy metabolism; Secondly, KD can directly act as a signaling molecule to improve mitochondrial function in skeletal muscle and stimulate skeletal muscle regeneration signaling molecules; Thirdly, KD can affect the gut microbiota to exert anti-inflammatory effects, enhance immunity, and thus protect SAW.Conclusion: KD has a protective effect on SAW, which includes improving energy metabolism, stimulating muscle regeneration signals, optimizing gut microbiota composition, and reducing inflammation and oxidative stress.